ABL Diagnostics won clearance to acquire Texcell, a viral safety and bioassay services provider spun out of the Pasteur Institute, in a €2.9 million deal. The transaction includes asset and inventory payments, employee retention, and continued operations at Texcell’s Genopole site, according to the company’s announcement. The acquisition expands ABL Dx capabilities in virology and biosafety services and follows a licensing agreement involving Pasteur Institute RNA sequencing-based HPV testing technology. For biotech manufacturing partners, deals like this highlight how service providers are building compliance-adjacent capabilities to support viral clearance and development workflows for clients.